Immunoglobulin G (IgG) is a type of antibody. It is a protein complex composed of four peptide chains—two identical heavy chains and two identical light chains arranged in a Y-shape typical of antibody monomers. Each IgG has two antigen binding sites. Representing approximately 75% of serumantibodies in humans, IgG is the most common type of antibody found in the circulation. IgG molecules are created and released by plasma B cells.
In the meantime, HLX11 can also enhance the tumour-killing activity of immune cells via antibody-dependent cell cytotoxicity ... The therapeutic candidate is a full-length IgG bi-specific antibody that acts by targeting HER2 and HER3.
As they act on different immune cells to IgG, IgE antibodies uniquely stimulate otherwise inactive immune cells in the 'microenvironment' surrounding the tumour to target the cancer cells directly.
In this study, a single intranasal dose of BPZE1 with and without co-administration of tetanus, diphtheria, and acellular pertussis vaccine (Tdap, Boostrix®) induced mucosal antibody responses.
As they act on different immune cells to IgG, IgE antibodies uniquely stimulate otherwise inactive immune cells in the ‘microenvironment’ surrounding the tumour to directly target the cancer cells.
VYVGART (efgartigimod PH20 SC) developed by Argenx is an antibody fragment designed to reduce pathogenic immunoglobulin G (IgG) antibodies by binding to the neonatal Fc receptor and blocking the IgG recycling process.